Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001767341 | SCV001991295 | uncertain significance | not provided | 2019-06-07 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect |
Institute for Clinical Genetics, |
RCV001767341 | SCV002010699 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001767341 | SCV005721217 | uncertain significance | not provided | 2024-04-12 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 219 of the NFIA protein (p.Thr219Pro). This variant is present in population databases (rs750817842, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with NFIA-related conditions. ClinVar contains an entry for this variant (Variation ID: 1306388). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |